Short Interest in Grace Therapeutics, Inc. (NASDAQ:GRCE) Increases By 70.1%

Grace Therapeutics, Inc. (NASDAQ:GRCE) was the recipient of a large growth in short interest in the month of February. As of February 13th, there was short interest totaling 65,459 shares, a growth of 70.1% from the January 29th total of 38,490 shares. Based on an average trading volume of 54,653 shares, the short-interest ratio is presently 1.2 days. Approximately 0.5% of the shares of the company are short sold. Approximately 0.5% of the shares of the company are short sold. Based on an average trading volume of 54,653 shares, the short-interest ratio is presently 1.2 days.

Institutional Trading of Grace Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. Stratos Wealth Partners LTD. bought a new stake in shares of Grace Therapeutics during the 4th quarter valued at about $39,000. SeaCrest Wealth Management LLC bought a new stake in Grace Therapeutics during the third quarter valued at approximately $42,000. Millington Financial Advisors LLC bought a new stake in Grace Therapeutics during the second quarter valued at approximately $59,000. XTX Topco Ltd purchased a new position in Grace Therapeutics in the 4th quarter worth approximately $106,000. Finally, Renaissance Technologies LLC increased its holdings in shares of Grace Therapeutics by 53.5% in the 4th quarter. Renaissance Technologies LLC now owns 129,781 shares of the company’s stock worth $449,000 after buying an additional 45,220 shares during the last quarter. Hedge funds and other institutional investors own 6.08% of the company’s stock.

Analyst Ratings Changes

GRCE has been the topic of several research analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Grace Therapeutics in a research note on Thursday, January 22nd. Wall Street Zen upgraded Grace Therapeutics to a “hold” rating in a research note on Friday, January 23rd. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $12.00.

Grace Therapeutics Stock Up 4.1%

GRCE traded up $0.17 on Friday, hitting $4.29. The company’s stock had a trading volume of 150,021 shares, compared to its average volume of 110,615. Grace Therapeutics has a 12 month low of $1.75 and a 12 month high of $4.30. The firm has a market cap of $66.37 million, a P/E ratio of -10.72 and a beta of 0.76. The company’s 50 day simple moving average is $3.68 and its 200-day simple moving average is $3.33.

Grace Therapeutics (NASDAQ:GRCE) last issued its earnings results on Thursday, February 12th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.05). Equities analysts predict that Grace Therapeutics will post -1.06 earnings per share for the current fiscal year.

Grace Therapeutics Company Profile

Grace Therapeutics, Inc (NASDAQ: GRCE) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for rare genetic diseases. By employing a proprietary platform that integrates advanced molecular biology and biologic engineering, the company focuses on identifying and optimizing gene-based and protein-based candidates designed to address well-defined genetic drivers of disease.

The company’s pipeline features multiple preclinical programs targeting lysosomal storage disorders and other inherited metabolic conditions.